Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Amicus Therapeutics (FOLD) Leases (2019 - 2025)

Amicus Therapeutics' Leases history spans 7 years, with the latest figure at $21.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 5.12% year-over-year to $21.1 million, compared with a TTM value of $21.1 million through Dec 2025, down 5.12%, and an annual FY2025 reading of $21.1 million, down 5.12% over the prior year.
  • Leases for Q4 2025 was $21.1 million at Amicus Therapeutics, down from $21.5 million in the prior quarter.
  • The five-year high for Leases was $30.4 million in Q2 2022, with the low at $20.6 million in Q4 2021.
  • Average Leases over 5 years is $24.7 million, with a median of $22.8 million recorded in 2024.
  • Year-over-year, Leases tumbled 31.19% in 2021 and then skyrocketed 43.47% in 2022.
  • Tracing FOLD's Leases over 5 years: stood at $20.6 million in 2021, then skyrocketed by 43.47% to $29.5 million in 2022, then decreased by 10.91% to $26.3 million in 2023, then decreased by 15.33% to $22.3 million in 2024, then decreased by 5.12% to $21.1 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Leases are $21.1 million (Q4 2025), $21.5 million (Q3 2025), and $22.0 million (Q2 2025).